INNOCARE - Verification Opinions and Publicity Statement on the List of Incentive Objects First Granted to the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan
INNOCARE - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
does not make any representation about the accuracy or completeness of this announcement and expressly disclaims any liability arising out of or in connection with all or any part of this announcement. We accept no liability for any loss caused by reliance on such content.
InnoCare Pharma Limited Nuocheng Jianhua Pharmaceutical Co., Ltd.
(Incorporated in the Cayman Islands with limited liability) (Stock code: 9969)
Overseas regulatory announcement
This announcement is made by InnoCheng Jianhua Pharmaceutical Co., Ltd. (the "Company") pursuant to the Securities and Exchange Commission of The Stock Exchange of Hong Kong Limited.
Made in accordance with Rule 13.10B of the Securities Listing Rules.
This is to set out the Company’s “Recommendations of the Remuneration Committee of the Board of Directors on the 2026 Science and Technology Plan” published on the website of the Shanghai Stock Exchange.
Verification Opinions and Publicity Statement on the List of Incentive Objects Granted for the First Time under the GEM Restricted Stock Incentive Plan.
By order of the board of directors
Nuocheng Jianhua Pharmaceutical Co., Ltd. Chairman and Executive Director Dr. Cui Jisong
Hong Kong, June 9, 2026
As at the date of this announcement, the Board of Directors includes Dr. Cui Jisong, Chairman and Executive Director; Dr. Zhao Renbin, Executive Director; Non-executive Directors
Dr. Shi Yigong and Mr. Xie Ronggang; and independent non-executive directors Ms. Hu Lan, Dr. Dong Dandan and Professor Guan Kunliang.
A-share code: 688428 A-share abbreviation: Nuocheng Jianhua Announcement number: 2026-023 Hong Kong stock code: 09969 Hong Kong stock abbreviation: Nuocheng Jianhua
Remuneration Committee of the Board of Directors of InnoCheng Jianhua Pharmaceutical Co., Ltd.
About the 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan
Verification opinions and disclosure of the list of first-time incentive recipients
The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records or misleading statements.
or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.
InnoCheng Jianhua Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held a directors' meeting on April 24, 2026
The meeting reviewed and approved the proposal of the "2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (Draft) and its Summary", etc.
Related motions. According to the "Administrative Measures for Equity Incentives of Listed Companies" (hereinafter referred to as the "Administrative Measures") and other relevant In accordance with relevant regulations, the company’s 2026 Science and Technology Innovation Board Restricted Stock Incentive Plan (hereinafter referred to as the "Incentive Plan")
The list and positions of incentive recipients for the first time were publicized within the company, and the remuneration committee of the board of directors combined with the public announcement
The list of incentive targets to be awarded for the first time under this incentive plan has been verified, and the relevant publicity and verification information have been verified.
The situation is as follows:
Publicity situation and verification methods
Publicity of the list of incentive targets
The company will conduct internal review of this incentive plan from May 21, 2026 to May 30, 2026.
The names and positions of the recipients of incentives to be awarded for the first time have been publicized for a total of 10 days. Employees of the company can
Provide opinions to the company's human resources department during the publicity period, and the human resources department will provide unified feedback to the remuneration committee of the board of directors
Yes.
As of the expiration of the publicity period, the Remuneration Committee of the Board of Directors has not received any comments from employees regarding the proposed incentive targets. Objection.
- Verification method of intended incentive objects
The Remuneration Committee of the Company’s Board of Directors has verified the list, status and
ID card, labor contract (or
Employment contract), the position held by the intended incentive target in the company, etc.
- Verification opinions
The Remuneration Committee of the Company's Board of Directors shall, in accordance with the "Management Measures" and "Innocent Jianhua Pharmaceutical Co., Ltd.'s 2026 Annual Report"
According to the provisions of the GEM Restricted Stock Incentive Plan (Draft) (hereinafter referred to as the "Incentive Plan"), the company The list of incentive recipients awarded for the first time under this incentive plan has been verified, and the verification opinions are as follows:
- Personnel included in the list of first-time incentive recipients of this incentive plan must possess the requirements of the People’s Republic of China
Company Law (hereinafter referred to as the "Company Law"), "Administrative Measures" and other laws, regulations and normative documents as well as the "Company Law"
Qualifications stipulated in the Company’s Articles of Association.
- The basic information of the incentive objects is true and there is no falsehood, intentional concealment or major misunderstanding.
- The incentive objects do not have the circumstances that stipulate in Article 8 of the "Administration Measures" that they are not allowed to become incentive objects:
(1) Determined as an unsuitable candidate by the stock exchange within the last 12 months;
(2) Have been deemed as inappropriate candidates by the China Securities Regulatory Commission and its dispatched agencies within the last 12 months;
(3) Administrative punishment by the China Securities Regulatory Commission and its dispatched agencies due to serious violations of laws and regulations in the past 12 months
impose fines or take market entry ban measures; (4) Those who are prohibited from serving as company directors or senior managers as stipulated in the Company Law;
(5) Laws and regulations prohibit participation in equity incentives of listed companies;
(6) Other circumstances determined by the China Securities Regulatory Commission.
- The personnel included in the list of first-time incentive recipients of this incentive plan comply with the "Management Measures" and "Shanghai
The conditions for incentive objects stipulated in the Stock Exchange's Science and Technology Innovation Board Stock Listing Rules and other documents are in line with the "Incentive Plan" Specified incentive conditions. The incentive targets of this incentive plan do not include independent non-executive directors, either individually or jointly.
Shareholders holding more than 5% of the shares of listed companies and their spouses, parents, and children.
In summary, the remuneration committee of the company's board of directors believes that the names of incentive objects awarded for the first time in the "Incentive Plan"
The personnel of the order all meet the conditions stipulated in relevant laws, regulations and normative documents, which serve as the "Incentive Plan"
The incentive objects are legal and valid. Announcement is hereby made.
Nuocheng Jianhua Pharmaceutical Co., Ltd.
Board Compensation Committee
June 10, 2026